OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers.... OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests. 詳細を表示
IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual...
Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.12 | -3.97350993377 | 3.02 | 3.16 | 2.9 | 19402 | 3.06082065 | CS |
4 | -0.14 | -4.60526315789 | 3.04 | 3.26 | 2.9 | 29475 | 3.07272435 | CS |
12 | -0.23 | -7.3482428115 | 3.13 | 3.34 | 2.8 | 18824 | 3.07325284 | CS |
26 | 0.21 | 7.80669144981 | 2.69 | 3.4799 | 2.55 | 28892 | 3.02126563 | CS |
52 | 0.4 | 16 | 2.5 | 4.34 | 2.08 | 33209 | 2.91371706 | CS |
156 | -69.5 | -95.9944751381 | 72.4 | 74 | 2.08 | 256925 | 19.05896169 | CS |
260 | -66.9 | -95.8452722063 | 69.8 | 125 | 2.08 | 317516 | 44.04102496 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約